ADCE D01
Alternative Names: ADCE-D01Latest Information Update: 13 Oct 2025
At a glance
- Originator ADCendo
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Soft tissue sarcoma
Most Recent Events
- 09 Oct 2025 ADCE D01 receives Fast Track designation for Soft tissue sarcoma [Parenteral] (Inoperable/Unresectable, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
- 05 Jun 2025 Phase-I/II clinical trials in Soft tissue sarcoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Monotherapy) in Belgium (Parenteral) (NCT06797999)
- 05 Jun 2025 Phase-I/II clinical trials in Soft tissue sarcoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (Parenteral) (NCT06797999)